Midazolam

Midazolam reduces both hypoxic and hypercapnic ventilatory drive. In patients with pre-existing severe respiratory insufficiency, this may precipitate respiratory failure requiring mechanical ventilation.

Unsupervised midazolam use in obstructive sleep apnea is absolutely contraindicated. Respiratory depression during sleep exacerbates existing upper airway obstruction.

Midazolam's centrally-mediated muscle relaxation exacerbates the neuromuscular junction deficit in myasthenia gravis. Respiratory muscle involvement can progress to respiratory failure.

Hepatic cirrhosis reduces midazolam clearance by approximately 37% and increases free (unbound) drug fraction from 1.9% to 4.9%. Dose reduction is required. Midazolam has a high hepatic extraction ratio, making its clearance flow-dependent.

The active glucuronide conjugate of 1'-hydroxymidazolam accumulates in renal failure, causing clinically significant prolonged sedation even when parent drug levels are sub-therapeutic. Effect is reversible with flumazenil. Dose reduction and enhanced monitoring required.

Patients with documented hypersensitivity to midazolam or any benzodiazepine should not receive the drug due to risk of allergic or anaphylactic reactions.

Benzodiazepines carry former FDA pregnancy category D classification. First trimester exposure carries risk of fetal harm. Use only when benefit clearly outweighs risk. No controlled human studies exist for midazolam specifically; animal studies show no teratogenicity.

Maternal midazolam administration near delivery causes neonatal sedation, hypotonia, and respiratory depression. Chronic maternal use may produce neonatal withdrawal syndrome.

Benzodiazepine class contraindication. Midazolam's mydriatic effect increases intraocular pressure, which can precipitate or worsen acute narrow-angle glaucoma.

Potent CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors) dramatically increase midazolam plasma concentrations. Dose reduction of 50–75% or more may be required. Not an absolute contraindication but requires substantial dose adjustment.

Opioid co-administration produces synergistic respiratory depression with midazolam. This combination is a leading cause of benzodiazepine-related overdose fatalities. Lowest effective doses of each agent should be used, with continuous respiratory monitoring.

Alcohol produces additive CNS and respiratory depression with midazolam. Concurrent use at peak effect is dangerous. Patients should avoid alcohol for the duration of midazolam's clinical effects.